Abstract
Purpose
Previous studies have reported a complex relationship between inflammatory cytokines and kidney stone disease (KSD). The purpose of this paper is to investigate the potential causal impact of inflammatory cytokines on KSD by Mendelian randomization (MR) analysis.
Methods
In our study, a thorough two-sample Mendelian randomization (MR) analysis was performed by us to determine the potential causal relationship between inflammatory cytokines and kidney stone disease. Utilizing GWAS summary data of inflammatory cytokines and KSD, we performed the first two-sample MR analysis. Genetic variants in GWASs related to inflammatory cytokines were employed as instrumental variables (IVs). The data on cytokines were derived from 14,824 participants and analyzed by utilizing the Olink Target-96 Inflammation Panel. GWAS summary data related to KSD (9713 cases and 366,693 controls) were obtained from the FinnGen consortium. The primary MR analysis method was Inverse variance weighted. Reverse MR analysis, Cochran's Q test, MR Egger, and MR-Pleiotropy RESidual Sum and Outlier (MR-PRESSO) were used to assess the stability of the results.
Results
91 cytokines were enrolled in the MR analysis after strict quality control of IV. The IVW analysis revealed 2 cytokines as risk factors for KSD: Cystatin D (OR 1.06, 95% CI 1.01–1.11), Fibroblast growth factor 5 (OR 1.06, 95% CI 1.00–1.12), suggesting they are positively associated with the occurrence of kidney stones. We also found 3 protective associations between cytokines and KSD: Artemin (OR 0.86, 95% CI 0.78–0.96), T-cell surface glycoprotein CD6 isoform (OR 0.92, 95% CI 0.88–0.98), STAM-binding protein (OR 0.83, 95% CI 0.69–0.99). There was no horizontal pleiotropy or significant heterogeneity in our MR analysis, as determined by the p-value results of our MR Egger’s intercept test, Cochrane Q-test, and MR-PRESSO, which were all > 0.05.
Conclusions
Our study explored a variety of inflammatory cytokines related to KSD through MR analysis, which validated several previous findings and provided some new potential biomarkers for KSD. However, the findings require further investigation to validate their exact functions in the pathogenesis and evolution of KSD.
Similar content being viewed by others
Data availability
The original contributions presented in this study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.
Abbreviations
- KSD:
-
Kidney stone disease
- NLR:
-
Neutrophil-to-lymphocyte ratio
- PNL:
-
Percutaneous nephrolithotomy
- FGF-5:
-
Fibroblast growth factor 5
- STAMBP:
-
STAM-binding protein
- GWAS:
-
Genome-wide association studies
- IVs:
-
Instrumental variable
- IVW:
-
Inverse variance weighted
- MR:
-
Mendelian randomization
- MR-PRESSO:
-
MR-Pleiotropy Residual Sum and Outlier method
- OR:
-
Odds ratio
- SNPs:
-
Single nucleotide polymorphism
- DNER:
-
Delta and Notch-like epidermal growth factor-related receptor
- MIP-1α:
-
Macrophage inflammatory protein 1α
- RTECs:
-
Renal tubular epithelial cells
- MCP-1:
-
Monocyte chemoattractant protein 1
- CSF-1:
-
Colony-stimulating factor 1
- CD5L:
-
CD5 antigen-like
- SCFA:
-
Short chain fatty acids
- PSHC:
-
Potassium sodium hydrogen citrate
References
Chewcharat A, Curhan G (2021) Trends in the prevalence of kidney stones in the United States from 2007 to 2016. Urolithiasis 49:27–39. https://doi.org/10.1007/s00240-020-01210-w
Rule AD, Lieske JC, Li X et al (2014) The ROKS nomogram for predicting a second symptomatic stone episode. J Am Soc Nephrol JASN 25:2878–2886. https://doi.org/10.1681/ASN.2013091011
Zhe M, Hang Z (2017) Nephrolithiasis as a risk factor of chronic kidney disease: a meta-analysis of cohort studies with 4,770,691 participants. Urolithiasis 45:441–448. https://doi.org/10.1007/s00240-016-0938-x
Rule AD, Lieske JC, Pais VM (2020) Management of kidney stones in 2020. JAMA 323:1961–1962. https://doi.org/10.1001/jama.2020.0662
Lee KS, Ha JS, Koo KC (2017) Significance of neutrophil-to-lymphocyte ratio as a novel indicator of spontaneous ureter stone passage. Yonsei Med J 58:988–993. https://doi.org/10.3349/ymj.2017.58.5.988
Abou Heidar N, Labban M, Bustros G, Nasr R (2020) Inflammatory serum markers predicting spontaneous ureteral stone passage. Clin Exp Nephrol 24:277–283. https://doi.org/10.1007/s10157-019-01807-5
Cetinkaya M, Buldu I, Kurt O, Inan R (2017) Platelet-to-lymphocyte ratio: a new factor for predicting systemic inflammatory response syndrome after percutaneous nephrolithotomy. Urol J 14:4089–4093
Dominguez-Gutierrez PR, Kwenda EP, Khan SR, Canales BK (2020) Immunotherapy for stone disease. Curr Opin Urol 30:183–189. https://doi.org/10.1097/MOU.0000000000000729
Lawlor DA, Harbord RM, Sterne JAC et al (2008) Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 27:1133–1163. https://doi.org/10.1002/sim.3034
Birney E (2022) Mendelian randomization. Cold Spring Harb Perspect Med 12:a041302. https://doi.org/10.1101/cshperspect.a041302
Davey Smith G, Hemani G (2014) Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet 23:R89-98. https://doi.org/10.1093/hmg/ddu328
Timpson NJ, Wade KH, Smith GD (2012) Mendelian randomization: application to cardiovascular disease. Curr Hypertens Rep 14:29–37. https://doi.org/10.1007/s11906-011-0242-7
Skrivankova VW, Richmond RC, Woolf BAR et al (2021) Strengthening the reporting of observational studies in epidemiology using mendelian randomization: the STROBE-MR statement. JAMA 326:1614–1621. https://doi.org/10.1001/jama.2021.18236
Zhao JH, Stacey D, Eriksson N et al (2023) Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets. Nat Immunol 24:1540–1551. https://doi.org/10.1038/s41590-023-01588-w
Burgess S, Thompson SG (2017) Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol 32:377–389. https://doi.org/10.1007/s10654-017-0255-x
Bowden J, Davey Smith G, Haycock PC, Burgess S (2016) Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol 40:304–314. https://doi.org/10.1002/gepi.21965
Sun AY, Hinck B, Cohen BR et al (2018) Inflammatory cytokines in the papillary tips and urine of nephrolithiasis patients. J Endourol 32:236–244. https://doi.org/10.1089/end.2017.0699
Matsuura K, Maehara N, Hirota A et al (2022) Two independent modes of kidney stone suppression achieved by AIM/CD5L and KIM-1. Commun Biol 5:1–13. https://doi.org/10.1038/s42003-022-03750-w
Mevissen TET, Komander D (2017) Mechanisms of deubiquitinase specificity and regulation. Annu Rev Biochem 86:159–192. https://doi.org/10.1146/annurev-biochem-061516-044916
Davies CW, Paul LN, Das C (2013) Mechanism of recruitment and activation of the endosome-associated deubiquitinase AMSH. Biochemistry 52:7818–7829. https://doi.org/10.1021/bi401106b
Bednash JS, Johns F, Patel N et al (2021) The deubiquitinase STAMBP modulates cytokine secretion through the NLRP3 inflammasome. Cell Signal 79:109859. https://doi.org/10.1016/j.cellsig.2020.109859
Swanson KV, Deng M, Ting JP-Y (2019) The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol 19:477–489. https://doi.org/10.1038/s41577-019-0165-0
Mangan MSJ, Olhava EJ, Roush WR et al (2018) Targeting the NLRP3 inflammasome in inflammatory diseases. Nat Rev Drug Discov 17:588–606. https://doi.org/10.1038/nrd.2018.97
Mulay SR, Kulkarni OP, Rupanagudi KV et al (2013) Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1β secretion. J Clin Invest 123:236–246. https://doi.org/10.1172/JCI63679
Anders H-J, Suarez-Alvarez B, Grigorescu M et al (2018) The macrophage phenotype and inflammasome component NLRP3 contributes to nephrocalcinosis-related chronic kidney disease independent from IL-1-mediated tissue injury. Kidney Int 93:656–669. https://doi.org/10.1016/j.kint.2017.09.022
Joshi S, Wang W, Peck AB, Khan SR (2015) Activation of the NLRP3 inflammasome in association with calcium oxalate crystal induced reactive oxygen species in kidneys. J Urol 193:1684–1691. https://doi.org/10.1016/j.juro.2014.11.093
Knauf F, Asplin JR, Granja I et al (2013) NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy. Kidney Int 84:895–901. https://doi.org/10.1038/ki.2013.207
Khan SR (2004) Role of renal epithelial cells in the initiation of calcium oxalate stones. Nephron Exp Nephrol 98:e55-60. https://doi.org/10.1159/000080257
Santos RF, Oliveira L, Carmo AM (2016) Tuning T cell activation: the function of CD6 at the immunological synapse and in T cell responses. Curr Drug Targets 17:630–639. https://doi.org/10.2174/1389450116666150531152439
Orta-Mascaró M, Consuegra-Fernández M, Carreras E et al (2016) CD6 modulates thymocyte selection and peripheral T cell homeostasis. J Exp Med 213:1387–1397. https://doi.org/10.1084/jem.20151785
Espinosa-Ortiz EJ, Eisner BH, Lange D, Gerlach R (2019) Current insights into the mechanisms and management of infection stones. Nat Rev Urol 16:35–53. https://doi.org/10.1038/s41585-018-0120-z
Sun L, Su Y, Jiao A et al (2023) T cells in health and disease. Signal Transduct Target Ther 8:235. https://doi.org/10.1038/s41392-023-01471-y
Zhao J, Lin H, Wang L et al (2021) Suppression of FGF5 and FGF18 expression by cholesterol-modified siRNAs promotes hair growth in mice. Front Pharmacol 12:666860. https://doi.org/10.3389/fphar.2021.666860
Zhang R, Li Y, Jia K et al (2020) Crosstalk between androgen and Wnt/β-catenin leads to changes of wool density in FGF5-knockout sheep. Cell Death Dis 11:407. https://doi.org/10.1038/s41419-020-2622-x
Higgins CA, Petukhova L, Harel S et al (2014) FGF5 is a crucial regulator of hair length in humans. Proc Natl Acad Sci U S A 111:10648–10653. https://doi.org/10.1073/pnas.1402862111
Newton-Cheh C, Johnson T, Gateva V et al (2009) Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 41:666–676. https://doi.org/10.1038/ng.361
Xi B, Shen Y, Reilly KH et al (2013) Recapitulation of four hypertension susceptibility genes (CSK, CYP17A1, MTHFR, and FGF5) in East Asians. Metabolism 62:196–203. https://doi.org/10.1016/j.metabol.2012.07.008
Khan SR, Pearle MS, Robertson WG et al (2016) Kidney stones. Nat Rev Dis Primer 2:1–23. https://doi.org/10.1038/nrdp.2016.8
Borghi L, Meschi T, Guerra A et al (1999) Essential arterial hypertension and stone disease. Kidney Int 55:2397–2406. https://doi.org/10.1046/j.1523-1755.1999.00483.x
Freije JP, Abrahamson M, Olafsson I et al (1991) Structure and expression of the gene encoding cystatin D, a novel human cysteine proteinase inhibitor. J Biol Chem 266:20538–20543. https://doi.org/10.1016/S0021-9258(18)54958-9
Tolomeo P, Butt JH, Kondo T et al (2023) Importance of cystatin C in estimating glomerular filtration rate: the PARADIGM-HF trial. Eur Heart J 44:2202–2212. https://doi.org/10.1093/eurheartj/ehad210
Washino S, Hosohata K, Miyagawa T (2020) Roles played by biomarkers of kidney injury in patients with upper urinary tract obstruction. Int J Mol Sci 21:5490. https://doi.org/10.3390/ijms21155490
Nashida T, Sato R, Haga-Tsujimura M et al (2013) Antigen-presenting cells in parotid glands contain cystatin D originating from acinar cells. Arch Biochem Biophys 530:32–39. https://doi.org/10.1016/j.abb.2012.12.009
Hill LJ, Di Pietro V, Hazeldine J et al (2017) Cystatin D (CST5): an ultra-early inflammatory biomarker of traumatic brain injury. Sci Rep 7:5002. https://doi.org/10.1038/s41598-017-04722-5
Daudon M, Jungers P, Bazin D, Williams JC (2018) Recurrence rates of urinary calculi according to stone composition and morphology. Urolithiasis 46:459–470. https://doi.org/10.1007/s00240-018-1043-0
Türk C, Petřík A, Sarica K et al (2016) EAU guidelines on diagnosis and conservative management of urolithiasis. Eur Urol 69:468–474. https://doi.org/10.1016/j.eururo.2015.07.040
Wang L, Cui Y, Zhang J, Zhang Q (2017) Safety of potassium-bearing citrate in patients with renal transplantation: a case report. Medicine (Baltimore) 96:e6933. https://doi.org/10.1097/MD.0000000000006933
Gridley CM, Sourial MW, Lehman A, Knudsen BE (2019) Medical dissolution therapy for the treatment of uric acid nephrolithiasis. World J Urol 37:2509–2515. https://doi.org/10.1007/s00345-019-02688-9
Zhu W, Zhao Z, Chou F et al (2019) Loss of the androgen receptor suppresses intrarenal calcium oxalate crystals deposition via altering macrophage recruitment/M2 polarization with change of the miR-185-5p/CSF-1 signals. Cell Death Dis 10:275. https://doi.org/10.1038/s41419-019-1358-y
Jin X, Jian Z, Chen X et al (2021) Short chain fatty acids prevent glyoxylate-induced calcium oxalate stones by GPR43-dependent immunomodulatory mechanism. Front Immunol 12:729382. https://doi.org/10.3389/fimmu.2021.729382
Acknowledgements
We express our gratitude to all SCALLOP Consortium studies for providing open access to the summary association statistics data. Genetic association estimates for kidney stone disease were obtained from the FinnGen consortium (www.finngen.fi/en). We thank all investigators for sharing these data.
Funding
This work was supported by the National Natural Science Foundation of China (Grant No. 81974092).
Author information
Authors and Affiliations
Contributions
D.F. Yuan and J.Y. Yang prepared and drafted the manuscript. X. Yu obtained funding for the study and provided critical revision of the manuscript for important intellectual content. W.S. Wu, Y. Amier, X.M. Li, and W.L. Wan assisted in obtaining data for the review article and revised the manuscript. Y.S. Huang and J.B. Li confirmed the authenticity of all the raw data.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Ethical approval and consent to participate
Our analysis used publicly available GWAS summary statistics. No new data were collected, and no new ethical approval was required.
Consent to publish
All authors have read and approved the final manuscript.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Yuan, D., Yang, J., Wu, W. et al. Inflammatory cytokines and their potential role in kidney stone disease: a Mendelian randomization study. Int Urol Nephrol 56, 3249–3257 (2024). https://doi.org/10.1007/s11255-024-04084-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-024-04084-8